Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
testosterone cypionate + radium-223
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
Testosterone cypionate + radium-223 is an investigational combination for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Testosterone cypionate is a synthetic androgen used in hormone therapy, while radium-223 is a targeted alpha-emitting radiopharmaceutical that selectively delivers radiation to bone metastases. The rationale for combining these agents is that testosterone cypionate may enhance the cytotoxic activity of radium-223, potentially increasing tumor cell death outside the primary sites targeted by radium-223 and mitigating side effects associated with radiopharmaceutical treatment. The combination is currently under study in clinical trials for advanced prostate cancer[1][4][6].
- Brand names
- XofigoDepo-Testosterone
- Other names
- radium-223 dichlorideradium223 dichlorideradium 223 dichloridetestosterone cypionateBipolar Androgen Therapy plus Radium-223
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on testosterone cypionate + radium-223.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on testosterone cypionate + radium-223.